Luxa Biotechnology Revenue and Competitors

USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Luxa Biotechnology's estimated annual revenue is currently $1.4M per year.(i)
  • Luxa Biotechnology's estimated revenue per employee is $201,000

Employee Data

  • Luxa Biotechnology has 7 Employees.(i)
  • Luxa Biotechnology grew their employee count by 40% last year.

Luxa Biotechnology's People

NameTitleEmail/Phone
1
Clinical Project Manager for Luxa Biotechnology LLC with the Neural Stem Cell InstituteReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$53.7M26716%N/AN/A
#2
$53.1M26421%N/AN/A
#3
$69.1M34426%N/AN/A
#4
$22.1M110-10%N/AN/A
#5
$151.8M75511%N/AN/A
#6
$63.9M31813%N/AN/A
#7
$29.9M14913%N/AN/A
#8
$1.7M17-6%$114.3MN/A
#9
$6.8M34-6%N/AN/A
#10
$12.5M62-9%N/AN/A
Add Company

What Is Luxa Biotechnology?

Luxa Biotechnology (LuxaBio) is a clinical-stage biotechnology company developing a novel adult RPE stem cell (RPESC) therapy for dry AMD. The proprietary adult RPESC-derived RPE stem cell product was developed at and licensed from the NSCI. LuxaBio is a partnership between the NSCI research institute and Y2 Solution, a Korean company to evaluate RPESC in a clinical trial to test the safety and efficacy of RPE progenitor stage progeny as a potential therapy for dry AMD. \n\nLuxaBio maintains a robust research program at NSCI to develop the RPESC as an effective, commercially viable cell product. The Phase 1/2a clinical trial of RPESC-RPE-4W for the Treatment of Dry Age-related Macular Degeneration includes the Cedars Sinai Biomanufacturing Center, Emmes, the University of Michigan Kellogg Eye Center, the National Eye Institute.

keywords:N/A

N/A

Total Funding

7

Number of Employees

$1.4M

Revenue (est)

40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.1M70%$6.1M
#2
$3.5M7-30%N/A
#3
$0.5M7N/AN/A
#4
$0.9M7N/AN/A
#5
$0.5M7N/AN/A